API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
Details:
The study demonstrated ability of masitinib to specifically inhibit another essential enzyme responsible for replication of virus: 3CLpro, the main protease of SARS-CoV-2. To date, masitinib is the only antiviral treatment in the world that specifically targets this protein.
Lead Product(s): Masitinib Mesylate,Isoquercitrin
Therapeutic Area: Infections and Infectious Diseases Product Name: AB1010
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2022
Details:
Study demonstrated ability of masitinib to specifically inhibit another essential enzyme responsible for replication of virus: 3CLpro, main protease of SARS-CoV-2. To date, masitinib is the only antiviral treatment in world that specifically targets this protein.
Lead Product(s): Masitinib Mesylate,Isoquercitrin
Therapeutic Area: Infections and Infectious Diseases Product Name: AB1010
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Details:
Masitinib is being developed as a novel SARS-CoV-2 protease inhibitor antiviral therapy in non-hospitalized (non-severe) and hospitalized (severe) COVID-19 patients. Masitinib is a orally administered tyrosine kinase inhibitor that targets mast cells and macrophages.
Lead Product(s): Masitinib Mesylate,Isoquercitrin
Therapeutic Area: Infections and Infectious Diseases Product Name: AB20001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021
Details:
SPA supports protocol for Phase 3 Trial of Isoquercetin to effect thromboembolic events in metastatic pancreatic cancer patients. Isoquercetin employs a novel pathway that is based on a new mechanism of action to prevent or reverse thrombus formation.
Lead Product(s): Isoquercitrin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ISQ950AN
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: FDA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 04, 2021
Details:
This collaboration follows the discovery by the University of Chicago that masitinib inhibits the main protease (3CLpro) necessary for the SARS-CoV-2 viral replication cycle.
Lead Product(s): Masitinib Mesylate,Isoquercitrin
Therapeutic Area: Infections and Infectious Diseases Product Name: AB20001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Chicago
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 06, 2021
Details:
The patents cover the inhibition of soluble P-selectin that helps to prevent and/or reduce thrombotic events. Quercis’ lead drug candidate ISQ950AN, acts as an antithrombotic with significantly lower risk of adverse events than existing therapies.
Lead Product(s): Isoquercitrin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ISQ950AN
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Quercis Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 21, 2021
Details:
This agreement will enable AB Science to fund the clinical development programme evaluating masitinib as a treatment for COVID-19.
Lead Product(s): Masitinib Mesylate,Isoquercitrin
Therapeutic Area: Infections and Infectious Diseases Product Name: AB1010
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: European Investment Bank
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 30, 2020
Details:
Starting from a library of 1,900 clinically used drugs, either approved for human use or in late stage clinical development, masitinib stood-out in its ability to completely inhibit activity of the SARS-CoV-2 main protease (3CLpro), thereby blocking viral replication.
Lead Product(s): Masitinib Mesylate,Isoquercitrin
Therapeutic Area: Infections and Infectious Diseases Product Name: AB1010
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2020